At the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Disease, Cerevance presented new clinical findings for its investigational Parkinson’s disease (PD) treatment, solengepras.

She has also received clinical trial support from BlueRock Therapeutics, Prevail Therapeutics, Neuroderm, Sun Pharma, Meira GTX, Bukwang, Insightec, Biogen, Genentech, Cerevance, UCB, and National ...

Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...

Merck is paying $25 million upfront to tap into Cerevance's NETSseq transcriptomics technology, used to discover proteins that are either over- or under-expressed in disease states, and is also ...

A stem cell–based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson's ...

Our Killer50 companies traditionally enjoy a strong start to a new year. In 2024, nine companies (six in the Life Sciences segment) raised a collective $711m. The big winners then were quantum ...